▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Keith Speights

TMFFishBiz

Keith Speights has been a contributing writer and analyst for The Motley Fool since 2012. Prior to The Motley Fool, Speights was CEO of a healthcare technology company; vice president of a healthcare software company; director of operations for a health insurer; and a technology consultant. He holds a B.S. in Industrial Engineering from Mississippi State University.

Recent Articles by Keith Speights

GettyImages-1296010631

Jul 9, 2021 by Keith Speights and Brian Orelli, PhD

Could Pfizer and Moderna Be in Trouble After the Latest COVID Vaccine Findings?

Maybe, but it's still too soon to know for sure.

Coronavirus with stock chart trending down

Jul 9, 2021 by Keith Speights

Why Novavax Stock Dropped This Week

Investors appear to be worried about the impact of the delta variant.

Smiling man and woman looking at smartphone

Jul 9, 2021 by Keith Speights

The Smartest Stocks to Buy With $500 Right Now

Think cannabis, technology, and social media.

Penny stocks

Jul 9, 2021 by Keith Speights

The 3 Most Profitable Robinhood Penny Stocks: Are They Buys?

Unfortunately, most profitable doesn't necessarily translate to actual profits in this case.

Coronavirus with earth inside it

Jul 8, 2021 by Keith Speights

Why Moderna and Novavax Stocks Are Jumping Today

COVID-19 concerns are driving the vaccine stocks higher.

Bitcoin symbol in a trashcan

Jul 8, 2021 by Keith Speights

Forget Cathie Wood's Planned Bitcoin ETF, These Stocks Are Smart Buys Now

All of them rank among Wood's favorite stocks.

Cannabis leaf on top of $100 bills

Jul 8, 2021 by Keith Speights

3 Marijuana Stocks That Could Be Millionaire Makers

They're already growing quickly.

Scientists looking at monitor in lab

Jul 7, 2021 by Keith Speights

Why CEL-SCI Stock Soared Today

The company attempted to clarify "confusion" related to its recent late-stage clinical results.

COVID vaccine - female healthcare professional

Jul 7, 2021 by Keith Speights

Why Moderna Stock Is Falling Today

The biotech reported good news, but investors appear to be worrying about the delta variant.

Doctor giving patient a vaccine shot

Jul 7, 2021 by Keith Speights

Could Pfizer and Moderna Now Face Their Second-Worst Scenario?

It's possible, but the dynamics of the fight against COVID-19 are changing rapidly.

Cannabis green light

Jul 7, 2021 by Keith Speights

3 Reasons Sundial Growers Could Be a Bigger Winner Than AMC Over the Next 5 Years

Never mind that AMC has trounced the Canadian pot stock so far this year.

Vaccine being given to teen boy

Jul 6, 2021 by Keith Speights

Why BioNTech and Moderna Stocks Are Slipping Today

New data from Israel appears to be weighing on both vaccine stocks.

Older couple smiling with laptop

Jul 6, 2021 by Keith Speights

3 Dividend Stocks That Are Dirt Cheap Right Now

Most stocks are priced at a premium. But these are bargains that also offer solid dividends.

Smiling Warren Buffett - TMF

Jul 5, 2021 by Keith Speights

3 Warren Buffett Stocks to Buy in July

You might call these the legendary investor's "A-list."

Movie theater with people smiling

Jul 5, 2021 by Keith Speights

3 Stocks to Buy That Are Critically Important to AMC's Future

AMC's business rebound hinges in large part on how well these companies' businesses perform.

GettyImages-1249961285 (1)

Jul 4, 2021 by Keith Speights and Brian Orelli, PhD

Why Coming in Second Could Be Great News for Pfizer and Moderna

And it could mean more bad news for AstraZeneca.

Wall Street sign with stock chart going up

Jul 4, 2021 by Keith Speights

Wall Street Predicts This Dividend Stock Will Soar More Than 40%

Here's why analysts are so bullish.

Light bulb and money on chalkboard with woman

Jul 4, 2021 by Keith Speights

Buying These 3 Robinhood Stocks Could Be the Smartest Investing Moves You'll Ever Make

I'm not exaggerating.

GettyImages-1127786324

Jul 3, 2021 by Keith Speights and Brian Orelli, PhD

Can Emergent BioSolutions Recover From Its Recent Blunders?

Yes, but it probably won't be an easy path.

GettyImages-1268224209

Jul 3, 2021 by Keith Speights and Brian Orelli, PhD

What Are the Odds That Vertex Strikes a Big Acquisition Deal?

It's a near certainty Vertex will make an acquisition -- unless it's acquired first.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services